Piramal Pharma Q2FY27 Results: Analyst call scheduled for Oct 28
- Piramal Pharma Limited will host a conference call on October 28, 2026
- The call will discuss Q2 and H1 FY2027 financial results
- Session runs from 10:00 am to 10:45 am IST
- Dial-in details provided for India, USA, UK, Singapore, and Hong Kong
*this image is generated using AI for illustrative purposes only.
Piramal Pharma Limited will host a conference call with investors and analysts on October 28, 2026, to discuss its Q2 and H1 FY2027 financial performance. The session is scheduled from 10:00 am to 10:45 am IST.
The company filed the intimation under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The filing was signed by Maneesh Sharma, Company Secretary & Compliance Officer, on October 16, 2026.
Conference Call Details
Participants can join via telephone or online registration. The following table outlines the dial-in numbers for various global locations:
| Location | Time | Telephone Number |
|---|---|---|
| India | 10:00 am IST | +91 22 6280 1461 / +91 22 7115 8320 |
| India (Toll Free) | 10:00 am IST | 1 800 120 1221 |
| USA (New York) | 12:30 am ET | 1 866 746 2133 |
| UK (London) | 04:30 am GMT | 0 808 101 1573 |
| Singapore | 12:30 pm SGT | 800 101 2045 |
| Hong Kong | 12:30 pm HKT | 800 964 448 |
Attendees are advised to use the Diamond Pass™ express join link for prior registration to reduce wait times.
About Piramal Pharma
Piramal Pharma operates through three key business segments: Piramal Pharma Solutions, an integrated contract development and manufacturing organization; Piramal Critical Care, a complex hospital generics business; and Piramal Consumer Healthcare. The company also holds a joint venture with AbbVie in ophthalmology through AbbVie Therapeutics India Private Limited.
What the Numbers Show
This announcement is purely procedural and contains no financial data. Consequently, no analytical observations regarding revenue, margins, or balance sheet health can be derived from this specific filing.
Historical Stock Returns for Piramal Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.25% | +0.22% | -3.24% | +32.57% | +1.74% | +6.10% |
How might the performance of Piramal Pharma Solutions' CDMO segment impact overall margins in Q2 FY2027?
What are the expected revenue contributions from the AbbVie ophthalmology joint venture in the upcoming half-year?
Will Piramal Critical Care's complex hospital generics segment show recovery or growth trends in H1 FY2027?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
